Aficamten + Fluvoxamine Interaction
Majorinteraction on record
Description
Strong CYP2C19 inhibitor that increases aficamten exposure, potentially increasing risk of heart failure due to systolic dysfunction. Dose reduction required.
Mechanism
CYP2C19 inhibition (strong); also weak to moderate CYP3A, weak CYP2C9, and weak CYP2D6 inhibition
Source: NLP:aficamten